Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849999 | 0.80 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL6488330 | 0.68 | SLC6A2 (0.57) | CHRNB2CHRNB4CHRNA3PDGFRBPDGFRA | |
| SCHEMBL6488329 | 0.68 | SLC6A2 (0.57) | CHRNB2CHRNB4CHRNA3PDGFRBPDGFRA | |
| SCHEMBL13850008 | 0.66 | SLC6A2 (0.49) | CHRNB2CHRNB4CHRNA3PDGFRBPDGFRA | |
| SCHEMBL7209977 | 0.66 | SLC6A2 (0.49) | CHRNB2CHRNB4CHRNA3PDGFRBPDGFRA | |
| SCHEMBL5620580 | 0.63 | DPP4 (0.41) | KDM1AMAOAMAOB | |
| SCHEMBL32667946 | 0.63 | PDGFRB (0.77) | PDGFRBPDGFRAPIK3CAMTORCYP2A6 | |
| SCHEMBL2772360 | 0.63 | PDGFRB (0.77) | PDGFRBPDGFRAPIK3CAMTORCYP2A6 | |
| SCHEMBL708999 | 0.61 | PDGFRB (0.75) | PDGFRBPDGFRAPIK3CAMTORCYP2A6 | |
| SCHEMBL24621829 | 0.60 | PDGFRB (0.72) | PDGFRBPDGFRAPIK3CAMTORCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118326-A1 | Nicotinic Acetylcholine Receptor Modulators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-07 | — | — | US | disclosed |
| US-20090118326-A1 | Nicotinic Acetylcholine Receptor Modulators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-07 | — | — | US | disclosed |
| WO-2009058120-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SRI INTERNATIONAL (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118326-A1 | Nicotinic Acetylcholine Receptor Modulators | CHRNA10, CHRNA6, CHRNA5 | CHRNB2 12/4885CHRNB4 17/4885CHRNA3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.